Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients

Journal of Neuro-Oncology

Volumn 106, Issue 1, 2012, Pages 121-125

  Norden, Andrew D ^a,b,c   Bartolomeo, Julia ^a   Tanaka, Shota ^a,b   Drappatz, Jan ^a,b,c   Ciampa, Abigail S ^a   Doherty, Lisa M ^a   Lafrankie, Debra C ^a   Ruland, Sandra ^a   Quant, Eudocia C ^a,b,c   Beroukhim, Rameen ^a,b,c   Wen, Patrick Y ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulation; Bevacizumab; Glioblastoma; Glioma; Intracerebral hemorrhage

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANAPLASTIC GLIOMA; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FISHER EXACT TEST; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; BRAIN NEOPLASMS; CEREBRAL HEMORRHAGE; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK;

EID: 83055181490     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0642-1     Document Type: Article

References (25)

1. LC Marras WH Geerts JR Perry 2000 The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review Cancer 89 640 646 10931464 10.1002/1097-0142(20000801)89:3<640::AID- CNCR20>3.0.CO;2-E 1:STN:280:DC%2BD3cvgt1aqsg%3D%3D (Pubitemid 30640111)
2. EO Jenkins D Schiff N Mackman NS Key 2010 Venous thromboembolism in malignant gliomas J Thromb Haemost 8 221 227 19912518 10.1111/j.1538-7836.2009. 03690.x 1:CAS:528:DC%2BC3cXisFKgs7w%3D
3. TJ Semrad R O'Donnell T Wun H Chew D Harvey H Zhou RH White 2007 Epidemiology of venous thromboembolism in 9,489 patients with malignant glioma J Neurosurg 106 601 608 17432710 10.3171/jns.2007.106.4.601 (Pubitemid 46536455)
4. AA Brandes E Scelzi G Salmistraro M Ermani C Carollo F Berti P Zampieri C Baiocchi MV Fiorentino 1997 Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study Eur J Cancer 33 1592 1596 9389920 10.1016/S0959-8049(97)00167-6 1:STN:280:DyaK1c%2FltFemuw%3D%3D (Pubitemid 28123480)
5. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY (2007) Medical management of brain tumor patients. Neurol Clin 25(4):1035-1071, ix (Pubitemid 47610811)
6. M Zangari LM Fink F Elice F Zhan DM Adcock GJ Tricot 2009 Thrombotic events in patients with cancer receiving antiangiogenesis agents J Clin Oncol 27 4865 4873 19704059 10.1200/JCO.2009.22.3875 1:CAS:528:DC%2BD1MXhtlKjtLvK
7. SR Nalluri D Chu R Keresztes X Zhu S Wu 2008 Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2277 2285 19017914 10.1001/jama.2008.656 1:CAS:528:DC%2BD1cXhtlyrt77O
8. HS Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey WK Yung N Paleologos MK Nicholas R Jensen J Vredenburgh J Huang M Zheng T Cloughesy 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733 4740 19720927 10.1200/JCO.2008.19.8721 1:CAS:528: DC%2BD1MXhtlGgtbbM
9. A Lai A Tran PL Nghiemphu WB Pope OE Solis M Selch E Filka WH Yong PS Mischel LM Liau S Phuphanich K Black S Peak RM Green CE Spier T Kolevska J Polikoff L Fehrenbacher R Elashoff T Cloughesy 2011 Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme J Clin Oncol 29 142 148 21135282 10.1200/JCO.2010.30.2729 1:CAS:528:DC%2BC3MXhvVahtb0%3D
10. JJ Raizer S Grimm MC Chamberlain MK Nicholas JP Chandler K Muro S Dubner AW Rademaker J Renfrow M Bredel 2010 A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas Cancer 116 5297 5305 20665891 10.1002/cncr.25462 1:CAS:528: DC%2BC3cXhsFWgtrrK
11. AD Norden GS Young K Setayesh A Muzikansky R Klufas GL Ross AS Ciampa LG Ebbeling B Levy J Drappatz S Kesari PY Wen 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 18316689 10.1212/01.wnl.0000304121.57857.38 1:CAS:528: DC%2BD1cXitlyqs7o%3D
12. PL Nghiemphu RM Green WB Pope A Lai TF Cloughesy 2008 Safety of anticoagulation use and bevacizumab in patients with glioma Neuro Oncol 10 355 360 18436627 10.1215/15228517-2008-009
13. JW Blom CJ Doggen S Osanto FR Rosendaal 2005 Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 715 722 15701913 10.1001/jama.293.6.715 1:CAS:528:DC%2BD2MXhtFeltL8%3D (Pubitemid 40216041)
14. FR Rickles S Patierno PM Fernandez 2003 Tissue factor, thrombin, and cancer Chest 124 58S 68S 12970125 10.1378/chest.124.3-suppl.58S 1:CAS:528:DC%2BD3sXotVensb4%3D (Pubitemid 37128437)
15. PM Fernandez SR Patierno FR Rickles 2004 Tissue factor and fibrin in tumor angiogenesis Semin Thromb Hemost 30 31 44 15034796 1:CAS:528: DC%2BD2MXotFyltA%3D%3D (Pubitemid 38457299)
16. NS Callander N Varki LV Rao 1992 Immunohistochemical identification of tissue factor in solid tumors Cancer 70 1194 1201 1381270 10.1002/1097- 0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO;2-E 1:STN:280:DyaK38zos1CjsQ%3D%3D
17. K Hamada J Kuratsu Y Saitoh H Takeshima T Nishi Y Ushio 1996 Expression of tissue factor correlates with grade of malignancy in human glioma Cancer 77 1877 1883 8646688 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID- CNCR18>3.0.CO;2-X 1:CAS:528:DyaK28XjtVGktbo%3D (Pubitemid 26125190)
18. PY Wen D Schiff S Kesari J Drappatz DC Gigas L Doherty 2006 Medical management of patients with brain tumors J Neurooncol 80 313 332 16807780 10.1007/s11060-006-9193-2 1:CAS:528:DC%2BD2sXptlGksQ%3D%3D (Pubitemid 44782910)
19. DE Gerber SA Grossman MB Streiff 2006 Management of venous thromboembolism in patients with primary and metastatic brain tumors J Clin Oncol 24 1310 1318 16525187 10.1200/JCO.2005.04.6656 1:CAS:528: DC%2BD28XjtlGhtrk%3D (Pubitemid 46622035)
20. G Meyer Z Marjanovic J Valcke B Lorcerie Y Gruel P Solal-Celigny C Le Maignan JM Extra P Cottu D Farge 2002 Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med 162 1729 1735 12153376 10.1001/archinte.162.15.1729 1:CAS:528:DC%2BD38Xms1Sgu7k%3D
21. AY Lee MN Levine RI Baker C Bowden AK Kakkar M Prins FR Rickles JA Julian S Haley MJ Kovacs M Gent 2003 Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 146 153 12853587 10.1056/NEJMoa025313 1:CAS:528: DC%2BD3sXltlOqsrg%3D (Pubitemid 36818784)
22. MH Cohen YL Shen P Keegan R Pazdur 2009 FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme Oncologist 14 1131 1138 19897538 10.1634/theoncologist.2009-0121 1:CAS:528:DC%2BC3cXjt1eqsw%3D%3D
23. R Yang GR Thomas S Bunting A Ko N Ferrara B Keyt J Ross H Jin 1996 Effects of vascular endothelial growth factor on hemodynamics and cardiac performance J Cardiovasc Pharmacol 27 838 844 8761851 10.1097/00005344- 199606000-00011 1:CAS:528:DyaK28XjsVOit7w%3D (Pubitemid 26000416)
24. TN Kreisl L Kim K Moore P Duic C Royce I Stroud N Garren M Mackey JA Butman K Camphausen J Park PS Albert HA Fine 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 19114704 10.1200/JCO.2008.16.3055 1:CAS:528:DC%2BD1MXjsVCjs7o%3D
25. Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM (2011) Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol